Niosomal encapsulation enhances thymoquinone-induced apoptosis in androgen-independent prostate cancer: an integrated DFT, docking, ADMET and cellular study
European Journal of Pharmaceutics and Biopharmaceutics · 2027-01 · 230 · 115287
DOI: 10.1016/j.ejpb.2026.115287 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2027-01. Verfasst von Gulsah Gedik und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology, Faculty of Pharmacy, Trakya University, 22030 Edirne, Türkiye. Electronic address: gulsahgedik@trakya.edu.tr. Die Arbeit nennt 105 Literaturangaben.
Abstract (Originalsprache)
Thymoquinone (TQ), the principal bioactive constituent of Nigella sativa seed oil, engages multiple anticancer pathways but is limited clinically by a sub-hourly plasma half-life and rapid hepatic clearance. We report a Span 60/cholesterol niosomal carrier (TQ-NIO) evaluated in PC-3 and LNCaP prostate cancer cells within an integrated quantum-chemical and target-engagement framework. TQ-NIO formed sub-micron vesicles (341.2 ± 12.1 nm; PDI 0.63 ± 0.13; ζ = -29.1 ± 0.8 mV) with 81.3 ± 0.8 % encapsulation efficiency and Korsmeyer-Peppas-controlled Fickian release (n = 0.28) over 72 h. Encapsulation halved the WST-1 IC50 of TQ in androgen-independent PC-3 cells (24 h: 13.5 → 6.5 µg mL-1; 48 h: 9.4 → 4.1 µg mL-1), while shifts in LNCaP cells were minimal, a cell-line-selective response. In PC-3, TQ-NIO amplified caspase-3/-9 activation 2.6-2.7-fold, raised p53 (3.7-fold) and Bax (2.4-fold), and suppressed Bcl-2 (0.50-fold) and survivin (0.40-fold); HUVECs retained near-control morphology. Free TQ inhibited violacein production in Chromobacterium violaceum (zone 20.3 ± 0.6 mm), and the niosomal form preserved anti-biofilm activity against Escherichia coli at dilutions where free TQ failed. Calculations at the B3LYP-D4/def2-TZVP level assigned TQ super-electrophilic character (ω ≈ 7.3 eV) with C7/C8 as Michael-acceptor centers and O4 as the dominant nucleophilic anchor, while docking against five oncologically relevant targets returned modest binding energies (-4.70 to -5.78 kcal mol-1) indicating possible interactions rather than demonstrated target engagement or functional inhibition. Niosomal encapsulation enhanced the in vitro antiproliferative and apoptosis-associated effects of TQ, particularly in PC-3 cells.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Trakya University, 22030 Edirne, Türkiye. Electronic address: gulsahgedik@trakya.edu.tr.
- Department of Medical Biology, Faculty of Medicine, Düzce University, 81620 Düzce, Türkiye.
- Department of Chemistry, Faculty of Sciences, Sakarya University, 54050 Sakarya, Türkiye.
- Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Trakya University, 22030 Edirne, Türkiye.
Zitieren
APA
Gedik, G., Dulger, G., Kiliccioglu, I., Musatat, A. B., Akkoyunlu, A., & Karagoz, U. (2027). Niosomal encapsulation enhances thymoquinone-induced apoptosis in androgen-independent prostate cancer: an integrated DFT, docking, ADMET and cellular study. European Journal of Pharmaceutics and Biopharmaceutics, 230, 115287. https://doi.org/10.1016/j.ejpb.2026.115287
Vancouver
Gedik G, Dulger G, Kiliccioglu I, Musatat AB, Akkoyunlu A, Karagoz U. Niosomal encapsulation enhances thymoquinone-induced apoptosis in androgen-independent prostate cancer: an integrated DFT, docking, ADMET and cellular study. European Journal of Pharmaceutics and Biopharmaceutics. 2027;230:115287. doi:10.1016/j.ejpb.2026.115287
BibTeX
@article{Gedik2027,
author = {Gedik, Gulsah and Dulger, Gorkem and Kiliccioglu, Ilker and Musatat, Ahmad Badreddin and Akkoyunlu, Aysegul and Karagoz, Ugur},
title = {Niosomal encapsulation enhances thymoquinone-induced apoptosis in androgen-independent prostate cancer: an integrated DFT, docking, ADMET and cellular study},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2027},
volume = {230},
pages = {115287},
doi = {10.1016/j.ejpb.2026.115287}
}
EUVIMED